GH Research PLC (GHRS) vs Novavax, Inc. (NVAX)

GH Research PLC and Novavax, Inc. are both Biotechnology companies. GH Research PLC and Novavax, Inc. are of similar size ($1.8B and $1.7B). GH Research PLC has the higher net margin (0.00% vs −59.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, GH Research PLC leads on 6 and Novavax, Inc. on 6.

Valuation

Metric GHRS NVAX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 4.23 11.47
P/B 4.41 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 3.20 10.73
Earnings yield (4.19%) (14.30%) (28.84%)
Free cash flow yield (3.27%) (2.52%) (23.03%)

Profitability

Metric GHRS NVAX Biotechnology median
Gross margin 0.00% 78.60% 65.16%
Operating margin 0.00% (56.58%) 0.00%
Net margin 0.00% (59.87%) 0.00%
Free cash flow margin 0.00% (10.20%) 0.00%
Return on equity (18.79%) 323.66% (57.72%)
Return on assets (18.16%) (21.62%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GHRS NVAX Biotechnology median
Revenue growth (TTM) — (61.64%) 5.64%
EPS growth (last fiscal year) (5.33%) 309.76% —
Revenue growth, 5-year CAGR — 18.76% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GHRS NVAX Biotechnology median
Debt to equity 0.00 (1.54) 0.00
Current ratio 28.70 2.33 4.73
Net debt to EBITDA 4.65 (1.04) 0.96

Dividend

Metric GHRS NVAX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GHRS NVAX Biotechnology median
Market cap 1.68b 1.75b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack